Skip to main content
SpringerLink
Log in
Book cover

Urological Oncology pp 817–833Cite as

The Hormonal Management of Metastatic Prostate Cancer

  • Chapter
  • First Online:

  • 1622 Accesses

Abstract

As many as 30 % of men treated with curative intent for localized prostate cancer will suffer a relapse, and a small number of men are diagnosed with prostate cancer which has already metastasized. For these men, androgen deprivation therapy is a highly effective treatment, although castration resistance inevitably develops. Over the last 20 years, clinical trials have yielded important advances in optimizing the use of androgen deprivation, such as the use of combined blockade versus monotherapy, and intermittent versus continuous treatment. In addition, there has been heightened awareness of the adverse consequences of androgen deprivation, specifically loss of bone mineral density, metabolic changes and cardiovascular morbidity. Future research will focus on incorporating novel agents into early treatment of metastatic prostate cancer, such as third generation androgen manipulating agents, non-androgen targeted therapies, and immune therapy.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Crawford ED. Epidemiology of prostate cancer. Urology. 2003;62(6):3–12.

    Article  PubMed  Google Scholar 

  2. Yu EE, Nathan FE, Higano CS. Role of detection of metastases as leading cause of screening failure in an ongoing phase III trial of zibotentan versus placebo in patients with non-metastatic castration-resistant prostate cancer (CRPC). J Clin Oncol. 2011;29(Suppl):135.

    Google Scholar 

  3. Desai BB, Quinn DI, Piatek CI, et al. Risk stratification and stage migration effect of novel imaging and biomarker technology in men with biochemical failure after local therapy for prostate cancer. J Clin Oncol. 2011;29(Suppl):e15196.

    Google Scholar 

  4. Jadvar H, Desai B, Ji L, et al. Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer. Clin Nucl Med. 2012;37(7):637–43.

    Article  PubMed Central  PubMed  Google Scholar 

  5. Lecouvet FE, Geukens D, Stainier A, et al. Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies. J Clin Oncol. 2007;25(22):3281–7.

    Article  PubMed  Google Scholar 

  6. Huggins C, Stevens RE, Hodges CV. Studies on prostatic cancer. Arch Surg. 1941;43(2):209–23.

    Article  CAS  Google Scholar 

  7. Schally AV, Kastin AJ, Coy DH. LH-releasing hormone and its analogues: recent basic and clinical investigations. Int J Fertil. 1976;21:1–30.

    CAS  PubMed  Google Scholar 

  8. Seidenfeld J, Samson D, Hasselblad V, et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and metaanalysis. Ann Intern Med. 2000;132:566–77.

    Article  CAS  PubMed  Google Scholar 

  9. Labrie F, Dupont A, Belanger A, et al. Simultaneous administration of pure antiandrogen, a combination necessary for the use of lutenizing hormone-releasing hormone agonists in the treatment of prostate cancer. Proc Natl Acad Sci. 1984;81:3861–3.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  10. Klotz L, Boccon-GIbaud L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month comparative, randomized, open-label parallel-group phase III study in patients with prostate cancer. BJU Int. 2008;102:1531–8.

    Article  CAS  PubMed  Google Scholar 

  11. Bubley GJ. Is the flare phenomenon clinically significant? Urology. 2001;58:5–9.

    Article  CAS  PubMed  Google Scholar 

  12. Brendler H, Chase WE, Scott WW. Prostatic cancer. Further Investigation of hormonal relationship. Arch Surg. 1950;61:433–40.

    Article  CAS  PubMed  Google Scholar 

  13. Attar RM, Takimoto CH, Gottardis MM. Castration-resistant prostate cancer: locking up the molecular escape routes. Clin Cancer Res. 2009;15:3251–5.

    Article  CAS  PubMed  Google Scholar 

  14. Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med. 1989;321:419–24.

    Article  CAS  PubMed  Google Scholar 

  15. Eisenberger M, Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med. 1998;339:1036–42.

    Article  CAS  PubMed  Google Scholar 

  16. Denis LJ, Keuppens F, Smith PH, et al. Maximum androgen blockade: final analysis of EORTC Phase III trial 30853. Eur Urol. 1998;33:144–51.

    Article  CAS  PubMed  Google Scholar 

  17. Caubet JF, Tausteson TD, Dong EW, et al. Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens. Urology. 1997;49:71–8.

    Article  CAS  PubMed  Google Scholar 

  18. Samson DJ, Seidenfeld J, Schmitt B, et al. Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer. 2002;95:361–76.

    Article  CAS  PubMed  Google Scholar 

  19. Prostate Cancer Trialists’ Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomized trials. Lancet. 2000;355:1491–8.

    Article  Google Scholar 

  20. Bruchovsky N, Rennie PS, Coldman AJ, et al. Effects of androgen withdrawal on the stem cell composition of the shionogi carcinoma. Cancer Res. 1990;50:2275–82.

    CAS  PubMed  Google Scholar 

  21. Akikura K, Bruchovsky N, Goldenberg SL, et al. Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen. Cancer. 1993;71:2782–90.

    Article  Google Scholar 

  22. Boccon-Gibod L, Hammerer P, Madersbacher S, et al. The role of intermittent androgen deprivation in prostate cancer. BJU Int. 2007;100:738–43.

    Article  CAS  PubMed  Google Scholar 

  23. de Leval J, Boca P, Youssef E, et al. Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naïve prostate cancer: results of a prospective randomized multicenter trial. Clin Prostate Cancer. 2002;1:163–71.

    Article  PubMed  Google Scholar 

  24. Calais da Silva FEC, Bono AV, Whelan P, et al. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomized phase 3 study of the South European Uroncological Group. Eur Urol. 2009;55:1269–77.

    Article  CAS  PubMed  Google Scholar 

  25. Klotz L, O’Callaghan J, Ding K, et al. A phase III randomized trial comparing intermittent versus continuous androgen suppression for patients with PSA progression after radical therapy: NCIC CTG PR.7/SWOG JPR.7/CTSU JPR.7/UK Intercontinental Trial CRUKE/01/013. J Clin Oncol. 2011;29 Suppl 7:3.

    Google Scholar 

  26. Iversen P, Tveter K, Varenhorst E, Scandinavian Casodex Cooperative Group. Randomised study of casodex 50mg monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. Scand J Urol Nephrol. 1996;30:93–8.

    Article  CAS  PubMed  Google Scholar 

  27. Boccardo F, Rubagotti A, Battaglia M, et al. Evaluation of tamoxifen and anastrazole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer. J Clin Oncol. 2006;23:808–15.

    Article  Google Scholar 

  28. Tay M-H, Kaufman DS, Regan MM, et al. Finasteride and bicalutamide as primary hormonal therapy in patients with advanced adenocarcinoma of the prostate. Ann Oncol. 2004;15:974–8.

    Article  PubMed  Google Scholar 

  29. McLeod DG, Iversen P, See WA, et al. Bicalutamide 150 plus standard care vs standard care alone for early prostate cancer. BJU Int. 2006;97:247–54.

    Article  CAS  PubMed  Google Scholar 

  30. Wooltorton E. Safety updates: repaglinide (GlucoNorm) and bicalutamide (Casodex). CMAJ. 2003;169:813.

    PubMed Central  Google Scholar 

  31. Eigl BJC, Eggener SE, Baybik J, et al. Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer. Clin Cancer Res. 2005;11:4905–11.

    Article  CAS  PubMed  Google Scholar 

  32. Pummer K, Lehnert M, Stettner H, Hubmer G. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer. Eur Urol. 1997;32:81–5.

    CAS  PubMed  Google Scholar 

  33. Taplin ME, Regan MM, Ko Y-J, et al. Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer. Clin Cancer Res. 2009;15:7099–105.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  34. Smith MR, Malkowicz SB, Chu F, et al. Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study. J Clin Oncol. 2008;26:1824–9.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  35. Oefelein MG, Ricchuiti V, Conrad W, et al. Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer. J Urol. 2001;166:1724–8.

    Article  CAS  PubMed  Google Scholar 

  36. Michaelson MD, Kaufman DS, Lee H, et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol. 2007;25:1038–42.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  37. Smith MR, Finkelstein JS, McGovern FJ, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab. 2002;87:599–603.

    Article  CAS  PubMed  Google Scholar 

  38. Levine GN, D’Amico AV, Berger P, et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American heart association, American cancer society, and the American urologic association. CA Cancer J Clin. 2010;60:194–201.

    Article  PubMed Central  PubMed  Google Scholar 

  39. Dicker AP. The safety and tolerability of low-dose irradiation for the management of gynaecomastia caused by antiandrogen monotherapy. Lancet Oncol. 2003;4:30–6.

    Article  PubMed  Google Scholar 

  40. Loprinzi CL, Sloan J, Stearns V, et al. Newer antidepressants and gabapentin for hot flashes: an individual patient pooled analysis. J Clin Oncol. 2009;27:2831–7.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  41. Loprinzi CL, Qin R, Baclueva EP, et al. Phase III, randomized double-blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes, N07C1. J Clin Oncol. 2010;28:641–7.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  42. Barton DL, LaVasseur BI, Sloan JA, et al. Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9. J Clin Oncol. 2010;28:3278–83.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  43. Boekhout AH, Vincent AD, Dalesio OB, et al. Management of hot flashes in patients who have breast cancer with venlafaxine and clonidine: a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2011;29(29):3862–8.

    Article  CAS  PubMed  Google Scholar 

  44. Deng G, Vickers AJ, Yeung KS, et al. Randomized, controlled trial of acupuncture for the treatment of hot flashes in breast cancer patients. J Clin Oncol. 2007;25:5584–90.

    Article  PubMed  Google Scholar 

  45. Diamond TH, Higano CS, Smith MR, et al. Osteoporosis in men with prostate carcinoma receiving androgen deprivation therapy. Cancer. 2004;100:892–9.

    Article  PubMed  Google Scholar 

  46. Smith MR, McGovern FJ, Zietman AL, et al. Pamidronate to prevent bone loss during androgen deprivation therapy for prostate cancer. N Engl J Med. 2001;345:948–55.

    Article  CAS  PubMed  Google Scholar 

  47. Smith MR, Eastham J, Gleason DM, et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol. 2003;169:2008–12.

    Article  CAS  PubMed  Google Scholar 

  48. Smith MR, Malkowicz SB, Chu F, et al. Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical trial. J Urol. 2008;179:152–5.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  49. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94:1458–68.

    Article  CAS  PubMed  Google Scholar 

  50. Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004;96:879–82.

    Article  CAS  PubMed  Google Scholar 

  51. Fizazi K, Carducci M, Smith MR, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomized, double-blind study. Lancet. 2011;377:813–22.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  52. Basaria S, Muller DC, Carducci MA, et al. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen deprivation therapy. Cancer. 2005;106:581–8.

    Article  Google Scholar 

  53. Keating NL, O’Malley J, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24:4448–56.

    Article  CAS  PubMed  Google Scholar 

  54. Braga-Basaria M, Dobs AS, Muller DC, et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol. 2006;24:3979–83.

    Article  PubMed  Google Scholar 

  55. D'Amico AV, Denham JW, Crook J, et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol. 2007;25(17):2420–5.

    Article  PubMed  Google Scholar 

  56. Elkins G, Marcus J, Stearns V, et al. Randomized trial of a hypnosis intervention for treatment of hot flashes among breast cancer survivors. J Clin Oncol. 2008;26:5022–6.

    Article  PubMed Central  PubMed  Google Scholar 

  57. Gerber GS, Chodak GW. Prostate specific antigen for assessing response to ketoconazole and prednisone in patients hormone refractory metastatic prostate cancer. J Urol. 1990;144:1177–9.

    CAS  PubMed  Google Scholar 

  58. Trachtenberg J, Halpern N, Pont A. Ketoconazole: a novel and rapid treatment for advanced prostate cancer. J Urol. 1983;130:152–3.

    CAS  PubMed  Google Scholar 

  59. Trump DL, Havlin KH, Messing EM, et al. High-dose ketoconazole in advanced hormone-refractory prostate cancer: endocrinologic and clinical effects. J Clin Oncol. 1989;7:1093–8.

    CAS  PubMed  Google Scholar 

  60. Williams D, Kerle DJ, Ware H, et al. Objective responses to ketoconazole therapy in patients with relapsed progressive prostatic cancer. Br J Urol. 1986;58:45–51.

    Article  CAS  PubMed  Google Scholar 

  61. Taplin ME, Xie W, Bubley GJ, et al. Docetaxel, estramustine, and 15-month androgen deprivation for men with prostate-specific antigen progression after definitive local therapy for prostate cancer. J Clin Oncol. 2006;24:5408–13.

    Article  CAS  PubMed  Google Scholar 

  62. Small EJ, Halabi S, Dawson NA, et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol. 2004;22:1025–33.

    Article  CAS  PubMed  Google Scholar 

  63. DeBono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995–2005.

    Article  CAS  Google Scholar 

  64. Lau KM, LaSpina M, Long J, Ho SM. Expression of estrogen receptor (ER)-a and ER-β in normal and malignant prostate epithelial cells: regulation by methylation and involvement in growth regulation. Cancer Res. 2000;60:3175–82.

    CAS  PubMed  Google Scholar 

  65. Li LC, Chui R, Nakajima K, et al. Frequent methylation of estrogen receptor in prostate cancer: correlation with tumor progression. Cancer Res. 2000;60:702.

    CAS  PubMed  Google Scholar 

  66. Smith DC, Redman BG, Flaherty LE, Li L, et al. A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer. Urology. 1998;52:257–60.

    Article  CAS  PubMed  Google Scholar 

  67. Aro J. Cardiovascular and all-cause mortality in prostatic cancer patients treated with estrogens or orchiectomy as compared to the standard population. Prostate. 1991;18(2):131–7.

    Article  CAS  PubMed  Google Scholar 

  68. Ockrim JL, Lalani EN, Laniado ME, et al. Transdermal estradiol therapy for advanced prostate cancer: forward to the past? J Urol. 2003;169:1735–7.

    Article  CAS  PubMed  Google Scholar 

  69. Kassouf W, Tanguay S, Aprikian AG. Nilutamide as second-line hormone therapy for prostate cancer after androgen ablation fails. J Urol. 2003;169:1742–4.

    Article  CAS  PubMed  Google Scholar 

  70. Scher HI, Beer TM, Higano CS, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study. Lancet. 2010;375:24–30.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, USC Norris Comprehensive Cancer Center, Los Angeles, CA, USA

    Tanya Barauskas Dorff MD & Jacek Pinski MD, PhD

Authors
  1. Tanya Barauskas Dorff MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jacek Pinski MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tanya Barauskas Dorff MD .

Editor information

Editors and Affiliations

  1. Department of Urology, Homerton University Hospital & Formerly St. Bartholomew's Hospital, London, United Kingdom

    Vinod H. Nargund

  2. Levine Cancer Institute, Carolinas HealthCare System, Charlotte, North Carolina, USA

    Derek Raghavan

  3. Radiation Oncology, Cedars Sinai Cancer Center, Los Angeles, California, USA

    Howard M. Sandler

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer-Verlag London

About this chapter

Cite this chapter

Dorff, T.B., Pinski, J. (2015). The Hormonal Management of Metastatic Prostate Cancer. In: Nargund, V., Raghavan, D., Sandler, H. (eds) Urological Oncology. Springer, London. https://doi.org/10.1007/978-0-85729-482-1_48

Download citation

  • DOI: https://doi.org/10.1007/978-0-85729-482-1_48

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-0-85729-481-4

  • Online ISBN: 978-0-85729-482-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation